• Thomas H. Lee Partners in April 2026 announced a majority investment in Celerion, a clinical pharmacology and bioanalytical services provider.
• Deal positions Celerion to capture rising demand for complex early-stage development and regulatory labeling studies as drug development complexity increases.
• THL cited Celerion’s integrated clinical research units and bioanalytical labs across North America and Europe as key differentiators.
• Partnership supports expansion of Celerion’s capacity and capabilities, with CEO Susan Thornton continuing to lead the business.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Thomas H. Lee Partners LP published the original content used to generate this news brief on May 28, 2026, and is solely responsible for the information contained therein.